In 2015, Nakano et al. retrospectively analyzed the long-term efficacy of GAL treatment in 279 very elderly AD patients from the Okayama Galantamine Study [26]; the patients were evaluated at baseline and after 3, 6, 12, and 24 months. This evidence concerns the gene GAL and Alzheimer disease.